Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Gravel

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
British Journal of Clinical Pharmacology|May 25, 2023
Considerations on the use of different comparators in pharmacovigilance: A methodological reviewChristopher A Gravel, Antonios Douros
Statistics in Medicine|October 31, 2017
Weighted estimation for confounded binary outcomes subject to misclassificationChristopher A Gravel, Robert W Platt
Pharmacoepidemiology and Drug Safety|January 15, 2025
Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular EventsWilliam Bai, Antonios Douros, Christopher A Gravel
Drug Safety|May 4, 2024
Comparators in Pharmacovigilance: A Quasi-Quantification Bias AnalysisChristopher A Gravel, William Bai, Antonios Douros
Pharmacoepidemiology and Drug Safety|February 13, 2019
Conditional validation sampling for consistent risk estimation with binary outcome data subject to misclassificationChristopher A Gravel, Patrick J Farrell, Daniel Krewski
Scientific Reports|November 20, 2025
A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxisFoteini Dermiki-Gkana, Christopher A Gravel, Christos Kontogiorgis, et al.
Statistics in Medicine|August 8, 2018
A validation sampling approach for consistent estimation of adverse drug reaction risk with misclassified right-censored survival dataChristopher A Gravel, Anup Dewanji, Patrick J Farrell, et al.
Pharmacoepidemiology and Drug Safety|May 14, 2026
A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis-Related Safety SignalsPriscilla O M V Lopes, Cory S Harris, Christopher A Gravel
Epidemiology (Cambridge, Mass.)|October 1, 2020
Postmyocardial Infarction Statin Exposure and the Risk of Stroke with Weighting for Outcome MisclassificationChristopher A Gravel, Kristian B Filion, Pauline M Reynier, et al.
British Journal of Clinical Pharmacology|March 13, 2023
Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysisChristopher A Gravel, Daniel Krewski, Donald R Mattison, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
British Journal of Clinical Pharmacology|May 25, 2023
Considerations on the use of different comparators in pharmacovigilance: A methodological reviewChristopher A Gravel, Antonios Douros
Statistics in Medicine|October 31, 2017
Weighted estimation for confounded binary outcomes subject to misclassificationChristopher A Gravel, Robert W Platt
Pharmacoepidemiology and Drug Safety|January 15, 2025
Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular EventsWilliam Bai, Antonios Douros, Christopher A Gravel
Drug Safety|May 4, 2024
Comparators in Pharmacovigilance: A Quasi-Quantification Bias AnalysisChristopher A Gravel, William Bai, Antonios Douros
Pharmacoepidemiology and Drug Safety|February 13, 2019
Conditional validation sampling for consistent risk estimation with binary outcome data subject to misclassificationChristopher A Gravel, Patrick J Farrell, Daniel Krewski
Scientific Reports|November 20, 2025
A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxisFoteini Dermiki-Gkana, Christopher A Gravel, Christos Kontogiorgis, et al.
Statistics in Medicine|August 8, 2018
A validation sampling approach for consistent estimation of adverse drug reaction risk with misclassified right-censored survival dataChristopher A Gravel, Anup Dewanji, Patrick J Farrell, et al.
Pharmacoepidemiology and Drug Safety|May 14, 2026
A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis-Related Safety SignalsPriscilla O M V Lopes, Cory S Harris, Christopher A Gravel
Epidemiology (Cambridge, Mass.)|October 1, 2020
Postmyocardial Infarction Statin Exposure and the Risk of Stroke with Weighting for Outcome MisclassificationChristopher A Gravel, Kristian B Filion, Pauline M Reynier, et al.
British Journal of Clinical Pharmacology|March 13, 2023
Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysisChristopher A Gravel, Daniel Krewski, Donald R Mattison, et al.
Pageof 4